Mylan, Inc. (MYL), one of the world’s leading generics and specialty pharmaceutical companies, was upgraded Tuesday to Outperform by Credit Suisse analyst Michael Faerm. He expects generic drug developers to perform well in the coming years as key blockbuster drugs lose patent protection and as generic pipeline opportunities grow.
MYL finished the session Tuesday at the highest close since May on strong volume, and it's likely to continue the trend to test the upper trend line of the bullish channel around the 21.60 area.
Preferred entry (buy stop) price is 20.80, with a stop loss at 20.20. See our Trading Rules page for more detail.